Premium
Effects of Diflunisal on Platelet Function and Fecal Blood Loss
Author(s) -
Green David,
Davies Richard O.,
Holmes Geoffrey I.,
Kohl Helga,
Lee Robyn B.,
Reynolds Nancy,
Schmid Frank R.,
Ts'ao Chung-hsin
Publication year - 1983
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/phar.1983.3.2p2.65
Subject(s) - diflunisal , platelet , aspirin , placebo , chemistry , malondialdehyde , serotonin , bleeding time , pharmacology , medicine , endocrinology , anesthesia , platelet aggregation , pathology , oxidative stress , receptor , alternative medicine
The effects of diflunisal, a nonacetylated difluorinated salicylate, on platelet function were compared with those of aspirin and placebo. In a randomized, double‐blind trial, normal subjects were given diflunisal, 250, 500, or 1,000 mg twice daily; aspirin, 650 or 1,300 mg twice daily; or placebo for 8‐day periods. Diflunisal, 250 mg, had no effect on platelet function, whereas 500 mg induced minimal inhibition of collagen‐induced release of platelet serotonin, and 1,000 mg inhibited platelet malondialdehyde production, moderately prolonged template bleeding times (p = NS), and increased fecal blood loss (p < 0.05). In contrast, aspirin, 650 mg, markedly inhibited collagen‐induced platelet aggregation and serotonin release, and 1,300 mg prolonged bleeding time (p < 0.01) and increased fecal blood loss (p < 0.01). The effects of aspirin lasted for up to 5 days, whereas changes induced by diflunisal had returned to baseline 24 hours after the drug was discontinued. We conclude that in doses in the same range as those of aspirin diflunisal inhibits platelet function less.